found Documents: 389

Announcements & Press Releases, Oncology / Immunology | 5 Apr 2024

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, April 5, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be prese

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 2 Apr 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

2 items

— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibito

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 28 Mar 2024

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

2 items

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 conditional approval and exp

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 22 Mar 2024

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, March 22, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of the Phase II/III clinical trial of sovleplenib

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 28 Feb 2024

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

2 items

Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA review in China, with Priority Review status an

LSE RNS Announcemnent (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 7 Feb 2024

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 2 Feb 2024

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday February 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals (“Inmagene”) has exercised options to license two

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group, Regulatory Notice | 1 Feb 2024

HUTCHMED to Announce 2023 Final Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, February 1, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 30 Jan 2024

HUTCHMED Receives ELUNATE^® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

2 items

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal canc

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 11 Jan 2024

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

1 item

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who

HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Dec 2023

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 13, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Secur

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Dec 2023

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, December 13, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announces that it has completed enrollment of its Phase II/III trial of fruquintinib in combi

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcement Topics, Announcements & Press Releases, Oncology / Immunology | 1 Dec 2023

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, December 1, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 9 Nov 2023

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

2 items

— FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade — — U.S. approval of FRUZAQLA triggers first milestone payment f

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 16 Oct 2023

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, October 16, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in com

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 29 Sep 2023

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

2 items

— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — Hong Kong, Shanghai & Florham Park, NJ — Friday, September 29, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUT

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 12 Sep 2023

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 12 Sep 2023

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in Chin

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 29 Aug 2023

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administrati

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 21 Aug 2023

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

2 items

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China, w

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 31 Jul 2023

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

2 items

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which�

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 20 Jul 2023

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 20, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administratio

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcement Topics, Oncology / Immunology | 10 Jul 2023

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, July 10, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I study in China of HMPL-415, an investigational novel selective a

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 26 Jun 2023

HUTCHMED to Announce 2023 Half-Year Financial Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, June 26, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2023 on Monday, July 31, 2023 at 7:00

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 16 Jun 2023

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

1 item

— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during�

HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 15 Jun 2023

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

2 items

— Application Includes Data from Phase III FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (“BSC”) vs. Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colore

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 9 Jun 2023

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, June 9, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data related to two novel investigational hematological malig

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 26 May 2023

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

2 items

— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO-2 and FRESCO clinical trials — OSAKA, Japan, CAMBRIDGE, Massachusetts, HONG KONG, SHANGHAI &

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 26 May 2023

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, May 25, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data related to HUTCHMED’s novel investigational cancer therapi

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 18 Apr 2023

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its New Drug Application (“NDA”) for fruquintinib in combination with paclitaxe

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 12 Apr 2023

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, April 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated clinical and non-clinical data related to five HUTCHMED investigation

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 11 Apr 2023

2022 Annual Report and Notice of Annual General Meeting

3 items

Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, April 11, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2022 Annual Report together with the Notice of Annual General Meeting and the Form

HKEX Announcement (PDF)LSE RNS Announcement (PDF)HKEX - Notice of Annual General Meeting

Announcements & Press Releases, Oncology / Immunology | 4 Apr 2023

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 4, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has consulted the China National Medical Products Administration (“NMPA”) and reach

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 31 Mar 2023

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

2 items

— NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China — — FRESCO-2 showed fruquintinib treatment reduced the risk of death by 34% in

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcement Topics, Oncology / Immunology | 14 Mar 2023

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23, 2023 and following the completion of

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 13 Mar 2023

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

1 item

Hong Kong, Shanghai & Florham Park, NJ — Monday, March 13, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today confirms that it does not have any exposure to Silicon Valley Bank (“SVB”) or Si

View Press Release (PDF)

Announcements & Press Releases, Group | 28 Feb 2023

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

2 items

Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by sign

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 27 Feb 2023

HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, February 27, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has completed patient enrollment of Phase II registration trial of amdizalisib

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 31 Jan 2023

HUTCHMED to Announce 2022 Final Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 31, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 23 Jan 2023

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

2 items

— HUTCHMED to receive US$400 million upfront on deal closing and up to US$730 million in potential future milestone payments, totaling up to US$1.13 billion, plus royalties on net sales — — Marketing authorization submissions in the U.S., Eur

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 18 Jan 2023

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Wednesday, January 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (�

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 3 Jan 2023

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 3, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical tria

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 19 Dec 2022

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer

2 items

— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe, Japan and Australia — — F

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 15 Nov 2022

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals

2 items

Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets Hong Kong, Shanghai & Florham Park, NJ — Tuesday, November 15, 2022: HUTCHMED (China) Limited (“HUTCHMED”)

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 14 Nov 2022

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

2 items

— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant �

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 27 Oct 2022

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 27, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of fruquintinib in combination with sintilimab a

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 10 Oct 2022

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

2 items

Hong Kong, Shanghai & Florham Park, NJ –– Monday, October 10, 2022: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm anti

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 8 Sep 2022

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

2 items

— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control with risk of disease progression or death reduced by 68% (0.32 HR) — — Results to be presented in a late-b

View Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 23 Aug 2022

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

2 items

— Trial met primary endpoint of overall survival and all secondary endpoints — — Selected as a late-breaker presentation — — Conference call and webcast to be held on Monday, September 12 at 2:00 pm Paris time to review the presentation a

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 9 Aug 2022

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

2 items

San Diego, Shanghai and Hong Kong — Tuesday, August 9, 2022: Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in the United State

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

2 3 4 5 6 7 8

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

HUTCHMED to Announce 2023 Final Results

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HUTCHMED to Announce 2023 Half-Year Financial Results

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

2022 Annual Report and Notice of Annual General Meeting

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China

HUTCHMED to Announce 2022 Final Results

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004

HUTCHMED Receives ELUNATE^® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer